

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/040081 A3

(51) International Patent Classification:

C12N 15/62 (2006.01) *A01K 67/027* (2024.01)
C12N 15/90 (2006.01) *C12N 15/09* (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2023/072253

(22) International Filing Date:

15 August 2023 (15.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/371,489 15 August 2022 (15.08.2022) US

(71) Applicant: JASPER THERAPEUTICS, INC. [US/US];
2200 Bridge Parkway, Suite 102, Redwood City, CA 94065
(US).

(72) Inventor: PANG, Wendy; c/o Jasper Therapeutics, Inc.,
2200 Bridge Parkway, Suite 102, Redwood City, CA 94065
(US).

(74) Agent: NIE, Alex, Y. et al.; Sheppard Mullin Richter &
Hampton LLP, 650 Town Center Drive, 10th Floor, Costa
Mesa, CA 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TRANSGENIC ANIMALS EXPRESSING CHIMERIC C-KIT PROTEIN




FIG. 1

(57) Abstract: The present disclosure describes methods of generating a transgenic cell or mouse that expresses a chimeric c-KIT protein capable of expression on mouse cells and binding to mouse stem cell factor (SCF) which can be inhibited by anti-human c-KIT inhibitors. The transgenic cells and mice can be used to test candidate anti-human c-KIT inhibitors.

[Continued on next page]

WO 2024/040081 A3

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

10 May 2024 (10.05.2024)